These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 8195615

  • 1. Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
    de Jong MD, Loewenthal M, Boucher CA, van der Ende I, Hall D, Schipper P, Imrie A, Weigel HM, Kauffmann RH, Koster R.
    J Infect Dis; 1994 Jun; 169(6):1346-50. PubMed ID: 8195615
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H.
    JAMA; 1996 Jul 10; 276(2):118-25. PubMed ID: 8656503
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhøj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H.
    JAMA; 1996 Jul 10; 276(2):111-7. PubMed ID: 8656502
    [Abstract] [Full Text] [Related]

  • 7. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
    Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA.
    J Infect Dis; 1997 Jun 10; 175(6):1502-6. PubMed ID: 9180194
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
    Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL.
    J Acquir Immune Defic Syndr (1988); 1994 Feb 10; 7(2):139-47. PubMed ID: 7905523
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
    de Jong MD, Vella S, Carr A, Boucher CA, Imrie A, French M, Hoy J, Sorice S, Pauluzzi S, Chiodo F, Weverling GJ, van der Ende ME, Frissen PJ, Weigel HM, Kauffmann RH, Lange JM, Yoon R, Moroni M, Hoenderdos E, Leitz G, Cooper DA, Hall D, Reiss P.
    J Infect Dis; 1997 Apr 10; 175(4):966-70. PubMed ID: 9086161
    [Abstract] [Full Text] [Related]

  • 16. Current clinical experience with nevirapine for HIV infection.
    Carr A, Cooper DA.
    Adv Exp Med Biol; 1996 Apr 10; 394():299-304. PubMed ID: 8815694
    [Abstract] [Full Text] [Related]

  • 17. In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).
    Jacobsen MA, van der Horst C, Causey DM, Dehlinger M, Hafner R, Mills J.
    J Infect Dis; 1991 Jun 10; 163(6):1219-22. PubMed ID: 1828075
    [Abstract] [Full Text] [Related]

  • 18. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    Kesho Bora Study Group, de Vincenzi I.
    Lancet Infect Dis; 2011 Mar 10; 11(3):171-80. PubMed ID: 21237718
    [Abstract] [Full Text] [Related]

  • 19. Lack of in vivo effect of granulocyte-macrophage colony-stimulating factor on human immunodeficiency virus type 1.
    Scadden DT, Pickus O, Hammer SM, Stretcher B, Bresnahan J, Gere J, McGrath J, Agosti JM.
    AIDS Res Hum Retroviruses; 1996 Aug 10; 12(12):1151-9. PubMed ID: 8844019
    [Abstract] [Full Text] [Related]

  • 20. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories.
    DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH, Rasheed S, Hollinger FB, Fischl MA, Volberding P.
    J Infect Dis; 1994 Apr 10; 169(4):713-21. PubMed ID: 8133085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.